Investor Relations
Stock Information
News & Events
Presentations and Publications
Financials
Corporate Governance
Shareholder Services

Investor Relations

Corporate Profile

Neothetics is a clinical-stage specialty pharmaceutical company focused on development and commercialization of therapeutics for the aesthetic market. Our current focus is on localized fat reduction and body contouring. Neothetics’ lead product candidate, LIPO-202, is a injectable treatment for undesirable, localized areas of fat with no downtime and causes no damage below the skin’s surface. Our clinical studies with LIPO-202 do not use local or systemic pain management before or after the procedure.

Stock Information
NEOT (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$1.16
Change (%)-0.00 (0.00%)
Volume10,319
Data as of 09/30/16 12:27 p.m. ET
Stock chart for: NEOT.O.  Currently trading at $1.16 with a 52 week high of $10.78 and a 52 week low of $0.53.
Recent Presentations
There are currently no items available.


Recent Publications
DateTitle
03/20/15
Download Documentation AESTHETIC TREATMENT OF CENTRAL ABDOMINAL BULGING (CAB) WITH LIPO-202 (SALMETEROL XINAFOATE FOR INJECTION)
Recent NewsMore >>
DateTitle  
08/11/16Neothetics Provides Business Update and Reports Second Quarter 2016 Financial Results
SAN DIEGO, Aug. 11, 2016 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT) today provided a business update on its strategic and operational initiatives and reported financial results for the second quarter 2016. “We are pleased with the progress made during the quarter and remain confident in our efforts to pursue development with a modified formulation of our lead asset, LIPO-202,” said Martha J. Demski, Neothetics’ Operating Committee and Board Member. “We look forward to moving LIPO-20... 
Download PDFPrinter Friendly Version
08/04/16Neothetics to Provide a Business Update and Release Second Quarter 2016 Financial Results Thursday, August 11, 2016
SAN DIEGO, Aug. 04, 2016 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT) today announced that it will provide a business update and release its second quarter 2016 financial results before the market opens on Thursday,  August 11, 2016. To receive Neothetics' press releases and other investor information, please go to the Investor Relations page of the company's website at investors.neothetics.com and register for email alerts. About Neothetics, Inc. Neothetics is a clinical-stage spec... 
Download PDFPrinter Friendly Version
05/12/16Neothetics Reports First Quarter 2016 Financial Results
SAN DIEGO, May 12, 2016 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT) today reported financial results and business progress for the first quarter 2016. First Quarter 2016 Highlights Neothetics plans to conduct a Phase 2 trial with a modified formulation of LIPO-202 in the third quarter of 2016 for the reduction of central abdominal bulging, which the company anticipates having top-line data from in the first quarter of 2017. This Phase 2 study will be a randomized, double-blind, ... 
Download PDFPrinter Friendly Version
05/05/16Neothetics to Release First Quarter 2016 Financial Results
SAN DIEGO, May 05, 2016 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market, today announced that it will release its first quarter 2016 financial results before the market opens on May 12, 2016. To receive Neothetics' press releases and other investor information, please go to the Investor Relations page of the company's website at investors.neothetics.com and register for email alerts. Abou... 
Download PDFPrinter Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Neothetics, Inc posts new information to the site. Just enter your e-mail address and click Submit.
 
Data Provided by Thomson Reuters
Minimum 20 minutes delayed